December 2025
1. HARVEY JE 3RD, Ryan M, Gunnarsson C, Chikermane S, et al
   Incremental cost of complications after TAVR and SAVR in contemporary clinical practice.
   Am Heart J. 2025;290:278-287.
   

   >> Share

   
   
2. ALSAIED T, Li R, Grant H, Schiff MD, et al
   Defining diastolic dysfunction post-Fontan: Threshold, risk factors, and associations with outcomes.
   Am Heart J. 2025;290:288-296.
   

   >> Share

   
   
3. ABDELHALIM AT, Reddy YVN, Miranda WR, Kamath PS, et al
   Prognostic value of liver biomarker scores for risk stratification in adults with Fontan palliation.
   Am Heart J. 2025;290:170-179.
   

   >> Share

   
   
4. LI Y, Schiff M, Olivieri LJ, Christopher AB, et al
   The long-term effect of the Fontan fenestration on clinical outcomes: A FORCE registry study.
   Am Heart J. 2025;290:105-114.
   

   >> Share

   
   
5. GALLEGOS FN, Bernstein D, Punn R, Long J, et al
   Systolic performance of the single ventricle, exercise capacity, and endothelial function in pediatric Fontan patients.
   Am Heart J. 2025;290:58-68.
   

   >> Share

   
   
6. WEI C, Sharma P, Paranjpe I, Heidenreich PA, et al
   Balancing cost and care: Analyzing commercial pricing for TAVR and SAVR.
   Am Heart J. 2025;290:1-5.
   

   >> Share

   
   November 2025
7. TOBE A, van Royen N, Amat-Santos IJ, Hudec M, et al
   Win ratio analysis of the LANDMARK trial.
   Am Heart J. 2025;289:1-5.
   

   >> Share

   
   October 2025
8. KIM KS, Belley-Cote EP, Walsh M, Wang A, et al
   Left atrial appendage occlusion study III-Kidney substudy.
   Am Heart J. 2025;288:90-100.
   

   >> Share

   
   September 2025
9. FEISTRITZER HJ, Jobs A, Zeymer U, Schneider S, et al
   Complete revascularization versus culprit-lesion only PCI in patients with NSTEMI and multivessel disease - Design and rationale of the randomized COMPLETE-NSTEMI trial.
   Am Heart J. 2025;287:94-106.
   

   >> Share

   
   August 2025
10. PARK HS, Suh CH, Ahn JM, Kang DY, et al
    Effect of Cerebral Embolic Protection Device on New Cerebral Embolism During Transcatheter Aortic Valve Replacement: A Prospective Sentinel Registry.
    Am Heart J. 2025 Aug 13:S0002-8703(25)00296-0. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    July 2025
11. VAKILPOUR A, Levin MG, Anyanwu EC, Denduluri S, et al
    Referral patterns and clinical outcomes in patients with severe aortic stenosis: A multicenter cohort study.
    Am Heart J. 2025 Jul 22:S0002-8703(25)00223-6. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
12. HAN M, Kang J, Kim B, Hwang D, et al
    The impact of body mass index (BMI) on antiplatelet monotherapy strategy for secondary prevention after percutaneous coronary intervention: A sub-study of the HOST-EXAM trial.
    Am Heart J. 2025 Jul 5:S0002-8703(25)00214-5. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
13. PITARO N, Nicolas J, Sartori S, Shneyderman M, et al
    Impact of Left Ventricular Function on Outcomes in Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention.
    Am Heart J. 2025 Jul 1:S0002-8703(25)00203-0. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    June 2025
14. KRASNIQI L, Skovbo JS, Hallas PJ, Brandes PA, et al
    Impact of statin treatment on postoperative atrial fibrillation in surgical aortic valve replacement.
    Am Heart J. 2025 Jun 13:S0002-8703(25)00194-2. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
15. CUTLIP DE, Mehran R, Doros G, Kaplinskiy V, et al
    Prospective randomized single-blind multicenter study to assess the safety and effectiveness of the SELUTION SLR 014 drug eluting balloon in the treatment of subjects with in-stent restenosis: Rationale and design.
    Am Heart J. 2025;284:11-19.
    

    >> Share

    
    May 2025
16. MAINI AS, Abu-Much A, Redfors B, Wollmuth JR, et al
    Outcomes Among Patients with Coronary Bifurcation Lesions Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention.
    Am Heart J. 2025 May 22:S0002-8703(25)00176-0. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
17. WHITE HD, O'Brien SM, Boden WE, Fremes SE, et al
    Use of Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Intervention and Associated Outcomes in the ISCHEMIA Trial.
    Am Heart J. 2025 May 20:S0002-8703(25)00165-6. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
18. GOLD ME, Kulkarni S, Yadalam A, Patel KJ, et al
    Cardiac Allograft Vasculopathy Mediates the Relationship Between Vitamin D Deficiency and Cardiovascular Mortality Following Heart Transplantation.
    Am Heart J. 2025 May 16:S0002-8703(25)00166-8. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
19. MESSINGER MC, Ashburn NP, Chait JS, Snavely AC, et al
    Risk of delayed percutaneous coronary intervention for STEMI in the Southeast United States.
    Am Heart J. 2025 May 13:S0002-8703(25)00157-7. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
20. KANDZARI DE, Latib A, Mylotte D, Ali ZA, et al
    Rationale and design of the prevail global trial program evaluating the prevail drug-coated balloon in patients with in-stent restenosis and de novo small vessel disease.
    Am Heart J. 2025;283:26-36.
    

    >> Share

    
    April 2025
21. JIANG Z, Chang S, Tao L, Luo J, et al
    The randomized controlled trial to compare temporary permanent pacemaker versus temporary pacemaker in patients with conduction block after transcatheter aortic valve replacement: rationale and design of the RECOVER trial: Randomized trial for Tempora
    Am Heart J. 2025 Apr 19:S0002-8703(25)00135-8. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
22. GOSVIG K, Goller J, Hansson NH, Brandes A, et al
    Rationale and design of the Anticoagulant Therapy after Left Atrial Appendage Closure (ATLAAC) Trial.
    Am Heart J. 2025 Apr 15:S0002-8703(25)00131-0. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
23. HAKEEM A, Ali Shah J, Kumar R, Khan K, et al
    Rationale and Design of the TADCLOT Trial: A Double Blind Randomized Controlled Trial Comparing Twice a Day Clopidogrel vs. Ticagrelor in Reducing Major Cardiac Events in Patients with Acute STEMI Undergoing Primary Percutaneous Coronary Intervention.
    Am Heart J. 2025 Apr 12:S0002-8703(25)00103-6. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
24. SOMSEN YBO, de Winter RW, Wu J, Hoek R, et al
    Design and rationale of the drug-coated balloon coronary angioplasty versus stenting for treatment of disease adjacent to a chronic total occlusion (Co-CTO) trial.
    Am Heart J. 2025 Apr 7:S0002-8703(25)00105-X. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
25. HORN N, Gartner L, Rastan AJ, Andrasi TB, et al
    Effects of a preoperative psychological expectation-focused intervention in patients undergoing valvular surgery - the randomized controlled ValvEx (valve patients' expectations) study.
    Am Heart J. 2025;282:156-169.
    

    >> Share

    
    
26. HSU AR, Karnakoti S, Abdelhalim AT, Miranda WR, et al
    Incidence and outcomes of prosthetic valve endocarditis in adults with congenital heart disease.
    Am Heart J. 2025;282:125-133.
    

    >> Share

    
    February 2025
27. AUER J, Lamm G
    High-risk features and probability of ischemic and bleeding events after percutaneous coronary intervention.
    Am Heart J. 2025 Feb 26:S0002-8703(25)00058-4. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
28. ANDO T, Nazif T, Briasoulis A, Afonso L, et al
    Clinical Outcomes of Direct Oral Anticoagulant Versus Warfarin After Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry.
    Am Heart J. 2025 Feb 26:S0002-8703(25)00057-2. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
29. ERRIQUEZ A, Colaiori I, Hakeem A, Guiducci V, et al
    Functional Coronary Angiography to Indicate and Guide Revascularization in STEMI Patients with Multivessel Disease: Rationale and Design of the AIR-STEMI trial: Functional coronary angiography in STEMI patients.
    Am Heart J. 2025 Feb 19:S0002-8703(25)00042-0. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
30. JORGENSEN TH, Thyregod HGH, Savontaus M, Bleie O, et al
    Transcatheter or Surgical Aortic Valve Replacement in patients with Severe Aortic Stenosis Aged 70 Years or Younger - a NOTION-2 sub-study.
    Am Heart J. 2025 Feb 12:S0002-8703(25)00034-1. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
31. GAO XF, Kan J, Wu HY, Chen J, et al
    Intravascular Imaging-guided versus Angiography-guided Percutaneous Coronary Intervention in Patients with Diabetes Mellitus: Rationale and design of an International, Multicenter, Randomized IVI-DIABETES Trial.
    Am Heart J. 2025 Feb 4:S0002-8703(25)00017-1. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
32. WANG G, Zhang R, Chen SL, Wang J, et al
    Targeted Therapy with a Localized abluminal Groove Low-Dose Sirolimus-Eluting Bioabsorbable Polymer Coronary Stent in Chronic Total Occlusions: The TARGET CTO Non-Inferiority Randomized Trial.
    Am Heart J. 2025 Feb 3:S0002-8703(25)00018-3. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
33. NAKASE M, Tomii D, Maznyczka A, Heg D, et al
    Five-year outcomes with self-expanding versus balloon-expandable TAVI in patients with left ventricular systolic dysfunction.
    Am Heart J. 2025;280:18-29.
    

    >> Share

    
    January 2025
34. BALDI C, Maio MD, Esposito L, Bellino M, et al
    How the COAPT trial affected the selection of patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge repair: insights from the GIOTTO Registry.
    Am Heart J. 2025 Jan 27:S0002-8703(25)00011-0. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
35. EFTEKHARI A, Christiansen EH, Lassen JF, Raungaard B, et al
    Randomized comparison of the combined Sirolimus eluting and endothelial progenitor cell Combo(TM) stent vs. Biolimus eluting absorbable polymer coated BioMatrix Alpha(TM) stent in patients undergoing percutaneous coronary intervention. Rationale and s
    Am Heart J. 2025 Jan 25:S0002-8703(25)00013-4. doi: 10.1016/j.ahj.2025.
    

    >> Share

    
    
36. VELDTMAN GR, Abualsaud A, Cohen S, Ordonez MV, et al
    Fontan circulation and systemic disease - a retrospective cohort analysis over 35 years of follow-up.
    Am Heart J. 2025;279:40-49.
    

    >> Share

    
    December 2024
37. CASSESE S, Simonetti F, Covarrubias HAA, Janisch M, et al
    Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy: Design and Rationale of ISAR-WAVE Trial.
    Am Heart J. 2024 Dec 20:S0002-8703(24)00337-5. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
38. POLLACK LM, Chang A, Thompson MP, Keteyian SJ, et al
    Hospital-level variation in cardiac rehabilitation metrics.
    Am Heart J. 2024 Dec 13:S0002-8703(24)00333-8. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
39. AARTS HM, Hemelrijk KI, Broeze GM, van Ginkel DJ, et al
    Deferral of routine percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation: rationale and design of the PRO-TAVI trial: the PRO-TAVI trial: rationale and design.
    Am Heart J. 2024 Dec 12:S0002-8703(24)00332-6. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    November 2024
40. REDDY KP, Shultz K, Eberly LA, Khatana SAM, et al
    Contribution margins and utilization of transcatheter aortic valve replacement versus surgical aortic valve replacement in the Medicare population.
    Am Heart J. 2024 Nov 27:S0002-8703(24)00302-8. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
41. ABRAHAM B, Suppah M, Farina J, Botros M, et al
    Impact of Moderate or Severe Mitral and Tricuspid Valves Regurgitation after Transcatheter Aortic Valve Replacement.
    Am Heart J. 2024 Nov 12:S0002-8703(24)00295-3. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
42. IANNOPOLLO G, Cocco M, Leone A, Sacca S, et al
    TRanscatheter Aortic-Valve Implantation with or without on-site Cardiac Surgery: the TRACS trial: TAVI in centers without on-site cardiac surgery.
    Am Heart J. 2024 Nov 4:S0002-8703(24)00281-3. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    October 2024
43. BARONE-ROCHETTE G, Vanzetto G, Danchin N, Steg PG, et al
    Rationale and design of the multicentric randomized EVAOLD trial: evaluation of a strategy guided by imaging versus routine invasive strategy in elderly patients with ischemia.
    Am Heart J. 2024 Oct 22:S0002-8703(24)00274-6. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
44. WHITLOCK RP, McCarthy PM, Gerdisch MW, Ramlawi B, et al
    The left atrial appendage exclusion for prophylactic stroke reduction (leaaps) trial: rationale and design.
    Am Heart J. 2024 Oct 10:S0002-8703(24)00268-0. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
45. THURAIAIYAH J, Jorgensen TH, Jensen JM, Fuchs A, et al
    Prospective study on the impact of different anti-thrombotic therapies on subclinical leaflet thickening and its temporal dynamics in transcatheter aortic valves - The NOTION-4 trial: Anti-thrombotic therapy and TAV-HALT.
    Am Heart J. 2024 Oct 5:S0002-8703(24)00264-3. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    September 2024
46. DE COCK E, Kautbally S, Timmermans F, Bogaerts K, et al
    Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: rationale and design of the COL BE PCI trial: Short title: Rationale and design of the COL BE PCI trial.
    Am Heart J. 2024 Sep 2:S0002-8703(24)00225-4. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
47. GATTI G, Fiore A, Ismail M, Dralov A, et al
    Prediction of 30-day mortality after surgery for infective endocarditis using risk scores: Insights from a European multicenter comparative validation study.
    Am Heart J. 2024;275:108-118.
    

    >> Share

    
    August 2024
48. DISMORR M, Granbom-Koski M, Ellfors E, Ruck A, et al
    Sex differences and long-term clinical outcomes after transcatheter aortic valve replacement: a SWEDEHEART study.
    Am Heart J. 2024 Aug 9:S0002-8703(24)00185-6. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
49. STAHLI BE, Linke A, Westermann D, Van Mieghem NM, et al
    A Randomized Comparison of the Treatment Sequence of Percutaneous Coronary Intervention and Transcatheter Aortic Valve Implantation: Rationale and Design of the TAVI PCI Trial.
    Am Heart J. 2024 Aug 7:S0002-8703(24)00184-4. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
50. MEDINA CK, Barnes SG, Felker GM, Mentz RJ, et al
    Severe obesity among patients with left ventricular assist devices.
    Am Heart J. 2024;274:130-133.
    

    >> Share

    
    
51. TERKELSEN CJ, Thim T, Freeman P, Dahl JS, et al
    Randomized comparison of TAVI valves: The Compare-TAVI trial.
    Am Heart J. 2024;274:84-94.
    

    >> Share

    
    
52. DUARTE VE, Yamamura K, Economy KE, Graf JA, et al
    The effects of pregnancy in subjects with repaired tetralogy of Fallot.
    Am Heart J. 2024;274:95-101.
    

    >> Share

    
    July 2024
53. BUTT JH, Yafasova A, Thein D, Begun X, et al
    Burden of Hospitalization During the First Year Following Transcatheter and Surgical Aortic Valve Replacement.
    Am Heart J. 2024 Jul 29:S0002-8703(24)00180-7. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
54. ERBAY A, Penzel L, Abdelwahed YS, Heuberger A, et al
    Prognostic impact of quantitative flow ratio (QFR)-consistent complete revascularization in patients with myocardial infarction and multivessel coronary artery disease.
    Am Heart J. 2024 Jul 19:S0002-8703(24)00177-7. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
55. ELLFORS E, Dismorr M, Ruck A, Settergren M, et al
    Predicted prosthesis-patient mismatch and long-term clinical outcomes after transcatheter aortic valve replacement: a SWEDEHEART study.
    Am Heart J. 2024 Jul 18:S0002-8703(24)00175-3. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
56. PERSITS I, Mirzai S, Sarnaik KS, Volk MC, et al
    Sarcopenia and Frailty in Patients Undergoing Transcatheter Aortic Valve Replacement.
    Am Heart J. 2024 Jul 18:S0002-8703(24)00173-X. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
57. POLSINELLI VB, Koczo A, Johnson AE, Elkayam U, et al
    Race, Hypertensive Disorders of Pregnancy and Outcomes in Peripartum Cardiomyopathy.
    Am Heart J. 2024 Jul 10:S0002-8703(24)00168-6. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
58. YANG Y, Chu TC, Suthar D, Beshish AG, et al
    Association of patient-level characteristics with long-term outcomes after Fontan palliation: Rationale, design, and baseline characteristics of the Pediatric Cardiac Care Consortium Fontan cohort study.
    Am Heart J. 2024;273:111-120.
    

    >> Share

    
    June 2024
59. ABOU-KARAM R, Tanguturi V, Cheng F, Elmariah S, et al
    Trial Designs A44002PZS Electronic Physician Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: Rationale, design, and methods of the randomized controlled DETECT AS Trial.
    Am Heart J. 2024 Jun 29:S0002-8703(24)00163-7. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
60. WU ZM, Kan J, Ye F, You W, et al
    PCSK9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Randomized, Double- Blind, Placebo-Controlled, Multicenter SHAWN Study.
    Am Heart J. 2024 Jun 26:S0002-8703(24)00157-1. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
61. MIYAWAKI N, Ishizu K, Shirai S, Miyahara K, et al
    Impact of the Clinical Frailty Scale on Long-term Outcomes After Transcatheter Aortic Valve Implantation.
    Am Heart J. 2024 Jun 12:S0002-8703(24)00139-X. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
62. BRUNO F, Rampone JM, Islas F, Gorla R, et al
    Echocardiographic and clinical features of patients developing prosthesis-patient mismatch after TAVR: insights from the Recovery TAVR registry.
    Am Heart J. 2024 Jun 3:S0002-8703(24)00137-6. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    May 2024
63. RICHARDSON C, Gilbert T, Aslam S, Brookes CL, et al
    Rationale and design of the Early valve replacement in severe ASYmptomatic Aortic Stenosis Trial.
    Am Heart J. 2024 May 29:S0002-8703(24)00128-5. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
64. LUPU L, Haberman D, Chitturi KR, Wermers JP, et al
    Overview of 2024 FDA Advisory Panel Meeting on the TriClip Transcatheter Tricuspid Valve Repair System.
    Am Heart J. 2024 May 29:S0002-8703(24)00126-1. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
65. KIM Y, Park H, Yoon HJ, Suh J, et al
    Fully Automated Quantitative Coronary Angiography Versus Optical Coherence Tomography Guidance for Coronary Stent Implantation (FLASH): Study Protocol for a Randomized Controlled Non-Inferiority Trial.
    Am Heart J. 2024 May 7:S0002-8703(24)00119-4. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
66. ZHANG F, Tian M, Wang X, Zhang H, et al
    Rationale and design of a Single-center Randomized Trial to Compare the Graft Patency between the Radial Artery and the No-touch Saphenous Vein in Coronary Artery Bypass Grafting Surgery (GRAFT-CAB Study).
    Am Heart J. 2024 May 4:S0002-8703(24)00117-0. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
67. LEMLEY BA, Okunowo O, Ampah SB, Wu L, et al
    Effect of patient factors, center, and era on Fontan timing: An observational study using the Pediatric Health Information Systems Database.
    Am Heart J. 2024;271:156-163.
    

    >> Share

    
    
68. GUO Y, Liu X, Li R, Ng S, et al
    Comparison of Down Sizing Strategy (HANGZHOU Solution) and Standard Annulus Sizing Strategy in type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement: Rationale and design of a randomized clinical trial.
    Am Heart J. 2024 May 1:S0002-8703(24)00098-X. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    April 2024
69. KIM MC, Ahn JH, Hyun DY, Lim Y, et al
    Timing of fractional flow reserve-guided complete revascularization in patients with ST-segment elevation myocardial infarction with multivessel disease: Rationale and design of the OPTION-STEMI trial.
    Am Heart J. 2024 Apr 17:S0002-8703(24)00078-4. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
70. ETIWY M, Flannery LD, Li SX, Morrison FJ, et al
    Examining Lack of Referrals to Heart Valve Specialists as Mechanisms of Potential Underutilization of Aortic Valve Replacement.
    Am Heart J. 2024 Apr 13:S0002-8703(24)00093-0. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    March 2024
71. GUINOT PG, Desebbe O, Besch G, Guerci P, et al
    Prospective randomized double-blind study to evaluate the superiority of Vasopressin versus Norepinephrine in the management of the patient at renal risk undergoing cardiac surgery with cardiopulmonary bypass (NOVACC trial).
    Am Heart J. 2024 Mar 14:S0002-8703(24)00068-1. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
72. KRUCOFF M, Spirito A, Baber U, Sartori S, et al
    Ticagrelor With or Without Aspirin Following Percutaneous Coronary Intervention in High-Risk Patients With Concomitant Peripheral Artery Disease: a subgroup analysis of the TWILIGHT randomized clinical trial.
    Am Heart J. 2024 Mar 6:S0002-8703(24)00053-X. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    
73. DOU D, Yuan S, Jia Y, Wang Y, et al
    The protocol of enhanced recovery after cardiac surgery in adult patients: a stepped wedge cluster randomized trial.
    Am Heart J. 2024 Mar 2:S0002-8703(24)00051-6. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    February 2024
74. ZHANG J, Kong XQ, Gao XF, Chen J, et al
    Transfemoral transcatheter aortic valve replacement with VitaFlow(TM) valve for pure native aortic regurgitation in patients with high surgical risk: Rationale and design of a prospective, multicenter, and randomized SEASON-AR trial.
    Am Heart J. 2024 Feb 25:S0002-8703(24)00049-8. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    January 2024
75. JAMMOUL N, Dupasquier V, Akodad M, Meunier PA, et al
    Long-term follow-up of balloon-expandable valves according to the implantation strategy: insight from the DIRECTAVI trial.
    Am Heart J. 2024 Jan 20:S0002-8703(24)00014-0. doi: 10.1016/j.ahj.2024.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share